News & Sentiment
York University’s Connected Minds and CIGI partner to strengthen global AI and neurotechnology governance
Toronto, ON, July 28, 2026 (GLOBE NEWSWIRE) -- York University’s Connected Minds: Neural and Machine Systems for a Healthy, Just Society and the Centre for International Governance Innovation (CIGI) are launching a 16-month pilot partnership to design and build new governance frameworks for...
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
1,707 articles
📰
Why Opko Health Stock Surged by 33% on Tuesday
It posted a beat-and-raise second quarter.
📰
United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?
Martine Rothblatt exercised options at $135.42 and sold at $530.42 under a pre-established Rule 10b5-1 plan, reducing her stake by just 1% while...
📰
Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case
The stock looks like a high-risk, high-reward play.
📰
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market MarketWatch
📰
[10-Q] ABBOTT LABORATORIES Quarterly Earnings Report - Stock Titan
[10-Q] ABBOTT LABORATORIES Quarterly Earnings Report Stock Titan
📰
Incyte Corporation (NASDAQ: INCY) lifts H1 2026 profit on drug sales and Vega deal - Stock Titan
Incyte Corporation (NASDAQ: INCY) lifts H1 2026 profit on drug sales and Vega deal Stock Titan
📰
3 Powerful AI Stocks Poised for the Next Massive Shift
AI's next winners may emerge from an overlooked part of the market. See how three software companies are turning proprietary expertise into a...
📰
This Healthcare Leader Just Made a Bet on Artificial Intelligence (AI): Time to Buy the Stock?
Bristol Myers keeps making moves to establish a strong foundation for the future.
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
Ecolab Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
ECL stock rises pre-market after earnings and revenues beat estimates, as pricing, volume growth and core-business demand lift organic sales.
Ecolab Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
ECL stock rises pre-market after earnings and revenues beat estimates, as pricing, volume growth and core-business demand lift organic sales.
Ecolab Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
ECL stock rises pre-market after earnings and revenues beat estimates, as pricing, volume growth and core-business demand lift organic sales.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
📰
More Than 1,100 AI Staffers Call for US to Pace Tech Growth - Bloomberg.com
More Than 1,100 AI Staffers Call for US to Pace Tech Growth Bloomberg.comEmployees at the world’s biggest AI companies are calling for a...
Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results?
BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion...
Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results?
BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion...
Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results?
BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion...
📰
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits - Fox Business
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits Fox BusinessJohnson & Johnson agrees to pay $5.5 billion in talc powder...
📰
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
The company isn't resting on its laurels.
📰
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
The company isn't resting on its laurels.
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.